Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKEXPSARC: Haploidentical NK Cells for Sarcomas
NCT02409576Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Feb 2015
- Primary completion
- Aug 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in Ewing sarcoma, rhabdomyosarcoma (RMS), sponsored by National University Hospital. Status: unknown.
02
Drugs
haploidentical natural killer cells
03
Conditions
Ewing sarcomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT02409576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409576.